Dashboard
Manage Tickers

MLYS Mineralys Therapeutics, Inc.

Nasdaq mineralystx.com


$ 44.85 $ -2.16 (-4.6 %)    

Thursday, 13-Nov-2025 15:48:13 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 608.86 $ -8.82 (-1.43 %)
DIA $ 475.16 $ -6.20 (-1.29 %)
SPY $ 672.46 $ -8.02 (-1.18 %)
TLT $ 89.45 $ -0.35 (-0.39 %)
GLD $ 383.12 $ -4.16 (-1.07 %)
$ 47.33
$ 45.95
$ 44.77 x 100
$ 44.97 x 56
$ 44.28 - $ 46.78
$ 8.24 - $ 47.65
1,802,199
na
3.75B
$ 1.54
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-10-2025 09-30-2025 10-Q
2 08-12-2025 06-30-2025 10-Q
3 05-12-2025 03-31-2025 10-Q
4 02-12-2025 12-31-2024 10-K
5 11-12-2024 09-30-2024 10-Q
6 08-13-2024 06-30-2024 10-Q
7 05-09-2024 03-31-2024 10-Q
8 03-21-2024 12-31-2023 10-K
9 11-07-2023 09-30-2023 10-Q
10 08-07-2023 06-30-2023 10-Q
11 05-15-2023 03-31-2023 10-Q
12 03-15-2023 12-31-2022 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-maintains-buy-on-mineralys-therapeutics-raises-price-target-to-56
HC Wainwright & Co. Maintains Buy on Miner...
11/12/2025 11:50:07

HC Wainwright & Co. analyst Matthew Caufield maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and raises the pr...

wells-fargo-maintains-overweight-on-mineralys-therapeutics-raises-price-target-to-55
Wells Fargo Maintains Overweight on Minera...
11/11/2025 14:27:03

Wells Fargo analyst Mohit Bansal maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Overweight and raises the price targe...

mineralys-therapeutics-q3-eps-052-beats-065-estimate
Mineralys Therapeutics Q3 EPS $(0.52) Beat...
11/10/2025 21:08:30

Mineralys Therapeutics (NASDAQ:MLYS) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate o...

earnings-scheduled-for-november-10-2025
Earnings Scheduled For November 10, 2025
11/10/2025 11:12:02

reported-friday-mineralys-therapeutics-showcases-broad-clinical-potential-of-lorundrostat-across-cardio-renal-metabolic-diseases
Reported Friday, Mineralys Therapeutics Sh...
11/10/2025 09:42:25

– Late-breaking presentation of Explore-CKD trial at ASN Kidney Week –– Pivotal Phase 3 Launch-HTN trial featured in the "B...

uncovering-potential-mineralys-therapeuticss-earnings-preview
Uncovering Potential: Mineralys Therapeuti...
11/07/2025 15:03:49

hc-wainwright--co-maintains-buy-on-mineralys-therapeutics-raises-price-target-to-52
HC Wainwright & Co. Maintains Buy on Miner...
10/30/2025 11:54:19

HC Wainwright & Co. analyst Matthew Caufield maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and raises the pr...

mineralys-therapeutics-presents-phase-2-explore-ckd-trial-of-lorundrostat-at-asn-kidney-week-2025
Mineralys Therapeutics Presents Phase 2 Ex...
10/21/2025 12:08:05

~ Late-breaking Phase 2 trial data evaluating the safety and efficacy of 25 mg of lorundrostat in participants with hypertensio...

mineralys-therapeutics-completes-enrollment-in-phase-2-explore-osa-trial-of-lorundrostat-in-participants-with-moderate-to-severe-osa-and-hypertension
Mineralys Therapeutics Completes Enrollmen...
09/30/2025 12:09:47

wells-fargo-maintains-overweight-on-mineralys-therapeutics-raises-price-target-to-50
Wells Fargo Maintains Overweight on Minera...
09/11/2025 12:36:56

Wells Fargo analyst Mohit Bansal maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Overweight and raises the price targe...

goldman-sachs-maintains-buy-on-mineralys-therapeutics-raises-price-target-to-52
Goldman Sachs Maintains Buy on Mineralys T...
09/09/2025 17:39:29

Goldman Sachs analyst Richard Law maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and raises the price target from...

hc-wainwright--co-reiterates-buy-on-mineralys-therapeutics-maintains-42-price-target
HC Wainwright & Co. Reiterates Buy on Mine...
09/08/2025 11:03:24

HC Wainwright & Co. analyst Matthew Caufield reiterates Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and maintains $4...

mineralys-therapeutics-presents-subgroup-data-from-phase-3-launch-htn-trial-at-aha-2025-highlighting-lorundrostats-efficacy-in-high-risk-hypertension-populations
Mineralys Therapeutics Presents Subgroup D...
09/05/2025 13:03:03

~Pivotal Launch-HTN trial of novel aldosterone synthase inhibitor lorundrostat enrolled a diverse range of participants with un...

bruker-mineralys-therapeutics-and-other-big-stocks-moving-lower-in-wednesdays-pre-market-session
Bruker, Mineralys Therapeutics And Other B...
09/03/2025 12:17:14

jefferies-maintains-hold-on-mineralys-therapeutics-raises-price-target-to-26
Jefferies Maintains Hold on Mineralys Ther...
09/03/2025 11:18:39

Jefferies analyst Dennis Ding maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Hold and raises the price target from $1...

why-alphabet-shares-are-trading-higher-by-around-6-here-are-20-stocks-moving-premarket
Why Alphabet Shares Are Trading Higher By ...
09/03/2025 09:23:11

reported-earlier-mineralys-therapeutics-prices-upsized-250m-public-offering-of-98m-shares-of-common-stock-at-2550-per-share
Reported Earlier, Mineralys Therapeutics P...
09/03/2025 06:46:10

mineralys-therapeutics-suspends-prospectus-supplement-for-atm-equity-offering
Mineralys Therapeutics Suspends Prospectus...
09/02/2025 21:08:23

-SEC Filing

mineralys-therapeutics-commences-175m-public-offering-with-2625m-over-allotment-option
Mineralys Therapeutics Commences $175M Pub...
09/02/2025 20:04:36

Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to targe...

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
09/02/2025 17:06:49

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION